Description

Dr. Al Hallak graduated from the University of Aleppo - Faculty of Medicine in 2005.
He works in Detroit, MI and 1 other location and specializes in Hematology/Oncology.
Dr. Al Hallak is affiliated with Henry Ford Allegiance Health.Dr. Al Hallak has a broad background in medicine, with specialized training in oncology.
He has profound clinical expertise in managing Gastrointestinal (GI) malignancies, in particular, pancreatic cancer.
Additionally, Dr. Al Hallak has robust clinical research training provided by the University of Michigan Master of Science program in clinical research design and statistical analysis, as well as a solid basic science training at Karmanos Cancer Institute.His research focus is on gastrointestinal malignancies, specifically pancreatic cancer.
The goal of his research is to better understand the molecular biology and microenvironment of GI cancers, discover new treatments and prevent treatment-induced toxicities.
He is able to translate a passion for improving treatment outcomes for GI cancer patients via conducting clinical trials (phase I-III), investigator-initiated and pharma-sponsored.
Dr. Hallak works through translational research to identify new biomarkers that help to individualize the treatment choice for patients and provide them with an accurate prediction of the treatment effect as well as a prognosis of their cancer.
He is leading the initiative to start a postmortem rapid autopsy program for pancreatic cancer patients in Detroit.
Additionally, he is a co-principal investigator on our Translational Pilot Trial to study the role of different microRNAs in predicting response and resistance to Gemcitabine and Nab-Paclitaxel when used as first-line therapy for metastatic or locally advanced unresectable Pancreatic cancer patients.
He is also a co-leader for the Phase II Clinical Trial to study the effect of adding XPO1 inhibitor (Selinexor) to Gemcitabine as a second-line treatment for patients with metastatic or locally advanced unresectable pancreatic cancer patients after non-Gemcitabine regimen failure.